Dermata's XYNGARI Phase 3 acne trial meets all primary endpoints with statistical significance

Dermata Therapeutics, Inc.

STAR-1 achieved all three primary endpoints: IGA success 29.4% vs 15.2% placebo (p<0.001).
Inflammatory lesion count reduced by 16.8 vs 13.1 (p<0.001); non-inflammatory by 17.3 vs 12.4 (p<0.001).
XYNGARI safe and well tolerated; no serious treatment-related adverse events.
Plans to initiate second Phase 3 STAR-2 trial in H2 2025, followed by NDA submission if positive.
CEO cites potential for partnership discussions; over 30 million U.S. acne patients annually.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.